应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
TCRX Tscan Therapeutics, Inc.
休市中 12-12 16:00:00 EST
1.01
-0.06
-5.61%
盘后
1.03
+0.02
+1.98%
18:33 EST
最高
1.08
最低
1.01
成交量
36.39万
今开
1.06
昨收
1.07
日振幅
6.07%
总市值
5,732万
流通市值
4,447万
总股本
5,675万
成交额
37.67万
换手率
0.83%
流通股本
4,403万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
TScan Therapeutics预计在截至12月31日的三个月内一次性支付230万美元的裁员费用
投资观察 · 11-20
TScan Therapeutics预计在截至12月31日的三个月内一次性支付230万美元的裁员费用
Tscan Therapeutics, Inc.2025财年第三财季实现净利润-35.71百万美元,同比减少19.47%
市场透视 · 11-17
Tscan Therapeutics, Inc.2025财年第三财季实现净利润-35.71百万美元,同比减少19.47%
TScan Therapeutics Inc - 预计2025年12月31日止三个月内将产生230万美元的一次性裁员费用 - SEC文件
美股速递 · 11-03
TScan Therapeutics Inc - 预计2025年12月31日止三个月内将产生230万美元的一次性裁员费用 - SEC文件
TScan暂停多重TCR-T疗法患者的进一步入组以优先发展血液学项目;重申计划在2026年第一季度公布数据
美股速递 · 11-03
TScan暂停多重TCR-T疗法患者的进一步入组以优先发展血液学项目;重申计划在2026年第一季度公布数据
Tscan Therapeutics, Inc.宣布将在2025年美国风湿病学会大会上进行口头报告和海报展示
美股速递 · 09-17
Tscan Therapeutics, Inc.宣布将在2025年美国风湿病学会大会上进行口头报告和海报展示
Tscan Therapeutics, Inc.盘中异动 急速上涨5.00%
市场透视 · 08-21
Tscan Therapeutics, Inc.盘中异动 急速上涨5.00%
Tscan Therapeutics, Inc.盘中异动 股价大跌5.30%
市场透视 · 03-11
Tscan Therapeutics, Inc.盘中异动 股价大跌5.30%
Tscan Therapeutics, Inc.2024财年实现净利润-1.27亿美元,同比减少42.34%
市场透视 · 03-10
Tscan Therapeutics, Inc.2024财年实现净利润-1.27亿美元,同比减少42.34%
Tscan Therapeutics, Inc.盘中异动 股价大跌5.45%报1.91美元
市场透视 · 03-06
Tscan Therapeutics, Inc.盘中异动 股价大跌5.45%报1.91美元
Needham:维持TScan Therapeutics(TCRX.US)评级,由买入调整至买入评级, 目标价由11.00美元调整至9.00美元。
金融界 · 03-06
Needham:维持TScan Therapeutics(TCRX.US)评级,由买入调整至买入评级, 目标价由11.00美元调整至9.00美元。
TScan Therapeutics 2024年第四季度每股收益$(0.30)未达预期$(0.27),销售额$66.5万未达预期$135万
财报速递 · 03-05
TScan Therapeutics 2024年第四季度每股收益$(0.30)未达预期$(0.27),销售额$66.5万未达预期$135万
Tscan Therapeutics, Inc.盘中异动 快速下跌5.00%
市场透视 · 03-03
Tscan Therapeutics, Inc.盘中异动 快速下跌5.00%
Tscan Therapeutics, Inc.盘中异动 急速拉升5.76%
市场透视 · 02-28
Tscan Therapeutics, Inc.盘中异动 急速拉升5.76%
Tscan Therapeutics, Inc.盘中异动 急速跳水5.12%
市场透视 · 02-27
Tscan Therapeutics, Inc.盘中异动 急速跳水5.12%
Tscan Therapeutics, Inc.盘中异动 大幅下跌5.07%
市场透视 · 02-24
Tscan Therapeutics, Inc.盘中异动 大幅下跌5.07%
Tscan Therapeutics, Inc.盘中异动 急速拉升5.02%
市场透视 · 02-22
Tscan Therapeutics, Inc.盘中异动 急速拉升5.02%
Tscan Therapeutics, Inc.盘中异动 临近午盘急速拉升5.44%报2.12美元
市场透视 · 02-20
Tscan Therapeutics, Inc.盘中异动 临近午盘急速拉升5.44%报2.12美元
Tscan Therapeutics, Inc.盘中异动 股价大涨5.12%
市场透视 · 02-19
Tscan Therapeutics, Inc.盘中异动 股价大涨5.12%
Tscan Therapeutics, Inc.盘中异动 早盘股价大涨5.39%
市场透视 · 02-14
Tscan Therapeutics, Inc.盘中异动 早盘股价大涨5.39%
Tscan Therapeutics, Inc.盘中异动 股价大跌5.06%
市场透视 · 02-04
Tscan Therapeutics, Inc.盘中异动 股价大跌5.06%
公司概况
公司名称:
Tscan Therapeutics, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
TScan Therapeutics, Inc.于2018年4月17日在特拉华州注册成立。该公司是一家临床前阶段的生物制药公司,专注于开发强大的T细胞受体工程T细胞或TCR-T疗法,用于治疗癌症患者。
发行价格:
--
{"stockData":{"symbol":"TCRX","market":"US","secType":"STK","nameCN":"Tscan Therapeutics, Inc.","latestPrice":1.01,"timestamp":1765573200000,"preClose":1.07,"halted":0,"volume":363876,"hourTrading":{"tag":"盘后","latestPrice":1.03,"preClose":1.01,"latestTime":"18:33 EST","volume":266,"amount":273.9402,"timestamp":1765582401532},"delay":0,"floatShares":44031318,"shares":56747993,"eps":-2.512828,"marketStatus":"休市中","change":-0.06,"latestTime":"12-12 16:00:00 EST","open":1.06,"high":1.075,"low":1.01,"amount":376670.3531988,"amplitude":0.060748,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.512828,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1626408000000,"exchange":"NASDAQ","adjPreClose":1.07,"preHourTrading":{"tag":"盘前","latestPrice":1.0408,"preClose":1.07,"latestTime":"09:25 EST","volume":700,"amount":730.01999,"timestamp":1765549543673},"postHourTrading":{"tag":"盘后","latestPrice":1.03,"preClose":1.01,"latestTime":"18:33 EST","volume":266,"amount":273.9402,"timestamp":1765582401532},"volumeRatio":0.4339995822926511},"requestUrl":"/m/hq/s/TCRX/wiki","defaultTab":"wiki","newsList":[{"id":"1146298895","title":"TScan Therapeutics预计在截至12月31日的三个月内一次性支付230万美元的裁员费用","url":"https://stock-news.laohu8.com/highlight/detail?id=1146298895","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146298895?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:29","pubTimestamp":1763569752,"startTime":"0","endTime":"0","summary":"11月3日 - TScan Therapeutics Inc ::*TSCAN THERAPEUTICS INC - 预计在截至12月31日的三个月内一次性支付230万美元的裁员费用 - SEC文件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","TCRX","BK4139"],"gpt_icon":0},{"id":"2584186666","title":"Tscan Therapeutics, Inc.2025财年第三财季实现净利润-35.71百万美元,同比减少19.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584186666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584186666?lang=zh_cn&edition=full","pubTime":"2025-11-17 00:02","pubTimestamp":1763308978,"startTime":"0","endTime":"0","summary":"11月17日,Tscan Therapeutics, Inc.公布财报,公告显示公司2025财年第三财季净利润为-35.71百万美元,同比减少19.47%;其中营业收入为2.51百万美元,同比增加139.05%,每股基本收益为-0.28美元。从资产负债表来看,Tscan Therapeutics, Inc.总负债1.18亿美元,其中短期债务6.90百万美元,资产负债比为2.23,流动比率为0.07。机构评级:截至2025年11月17日,当前有5家机构对Tscan Therapeutics, Inc.目标价做出预测,其中目标均价为6.60美元,其中最低目标价为4.00美元,最高目标价为10.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117000319950817ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117000319950817ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TCRX"],"gpt_icon":0},{"id":"1182618270","title":"TScan Therapeutics Inc - 预计2025年12月31日止三个月内将产生230万美元的一次性裁员费用 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1182618270","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182618270?lang=zh_cn&edition=full","pubTime":"2025-11-03 19:38","pubTimestamp":1762169889,"startTime":"0","endTime":"0","summary":"TScan Therapeutics Inc - 预计2025年12月31日止三个月内将产生230万美元的一次性裁员费用 - SEC文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TCRX","BK4139","BK4539"],"gpt_icon":0},{"id":"1181930115","title":"TScan暂停多重TCR-T疗法患者的进一步入组以优先发展血液学项目;重申计划在2026年第一季度公布数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1181930115","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181930115?lang=zh_cn&edition=full","pubTime":"2025-11-03 19:33","pubTimestamp":1762169589,"startTime":"0","endTime":"0","summary":"TScan宣布暂停对多重TCR-T疗法患者的进一步入组,旨在优先推进血液学领域的发展。同时,公司重申将在2026年第一季度公布相关数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TCRX","BK4539"],"gpt_icon":0},{"id":"1105851613","title":"Tscan Therapeutics, Inc.宣布将在2025年美国风湿病学会大会上进行口头报告和海报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1105851613","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105851613?lang=zh_cn&edition=full","pubTime":"2025-09-17 19:01","pubTimestamp":1758106903,"startTime":"0","endTime":"0","summary":"Tscan Therapeutics, Inc.宣布将在2025年美国风湿病学会大会上进行口头报告和海报展示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TCRX","BK4139","BK4539"],"gpt_icon":0},{"id":"2561479223","title":"Tscan Therapeutics, Inc.盘中异动 急速上涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561479223","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561479223?lang=zh_cn&edition=full","pubTime":"2025-08-21 23:28","pubTimestamp":1755790109,"startTime":"0","endTime":"0","summary":"北京时间2025年08月21日23时28分,Tscan Therapeutics, Inc.股票出现波动,股价急速拉升5.00%。Tscan Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.74%。其相关个股中,Protagenic Therapeutics Inc C/Wts 26/04/2026 、知临集团、Protagenic Therapeutics, Inc.涨幅较大,Protagenic Therapeutics, Inc.、知临集团、Tharimmune, Inc.较为活跃,换手率分别为14747.84%、3300.75%、1179.10%,振幅较大的相关个股有Protagenic Therapeutics Inc C/Wts 26/04/2026 、Protagenic Therapeutics, Inc.、知临集团,振幅分别为459.84%、116.23%、113.39%。Tscan Therapeutics, Inc.公司简介:TScan Therapeutics Inc 是一家生物制药公司,专注于开发用于治疗癌症患者的 T 细胞受体 工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250821232829a496939e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250821232829a496939e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","LENZ","TCRX","BK4539"],"gpt_icon":0},{"id":"2518220126","title":"Tscan Therapeutics, Inc.盘中异动 股价大跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518220126","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518220126?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:49","pubTimestamp":1741628968,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日01时49分,Tscan Therapeutics, Inc.股票出现波动,股价急速下跌5.30%。Tscan Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.82%。其相关个股中,Aeon Biopharma, Inc.、Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.涨幅较大,Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.较为活跃,换手率分别为5466.60%、3825.64%、991.14%,振幅较大的相关个股有Aeon Biopharma, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Biodexa Pharmaceuticals Plc,振幅分别为90.44%、88.14%、58.34%。Tscan Therapeutics, Inc.公司简介:TScan Therapeutics Inc 是一家生物制药公司,专注于开发用于治疗癌症患者的 T 细胞受体 工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311014928abf35ac8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311014928abf35ac8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TCRX","BK4139","BK4539"],"gpt_icon":0},{"id":"2518748289","title":"Tscan Therapeutics, Inc.2024财年实现净利润-1.27亿美元,同比减少42.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518748289","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518748289?lang=zh_cn&edition=full","pubTime":"2025-03-10 00:00","pubTimestamp":1741536046,"startTime":"0","endTime":"0","summary":"3月10日,Tscan Therapeutics, Inc.公布财报,公告显示公司2024财年净利润为-1.27亿美元,同比减少42.34%;其中营业收入为2.82百万美元,同比减少86.60%,每股基本收益为-1.14美元。从资产负债表来看,Tscan Therapeutics, Inc.总负债1.30亿美元,其中短期债务4.57百万美元,资产负债比为2.86,流动比率为0.09。机构评级:截至2025年3月10日,当前有7家机构对Tscan Therapeutics, Inc.目标价做出预测,其中目标均价为10.29美元,其中最低目标价为3.00美元,最高目标价为15.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000113a268980a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000113a268980a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TCRX"],"gpt_icon":0},{"id":"2517443609","title":"Tscan Therapeutics, Inc.盘中异动 股价大跌5.45%报1.91美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517443609","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517443609?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:43","pubTimestamp":1741193030,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日00时43分,Tscan Therapeutics, Inc.股票出现异动,股价快速下挫5.45%。Tscan Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.04%。其相关个股中,Chimerix, Inc.、Nutriband Inc C/Wts 、Celularity Inc.涨幅较大,Silexion Therapeutics Corp、Tc Biopharm Plc、Bioxcel Therapeutics, Inc.较为活跃,换手率分别为912.60%、299.54%、282.78%,振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 ,振幅分别为82.59%、54.27%、41.26%。Tscan Therapeutics, Inc.公司简介:TScan Therapeutics Inc 是一家生物制药公司,专注于开发用于治疗癌症患者的 T 细胞受体 工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306004351abe9d8d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306004351abe9d8d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TCRX","BK4539","BK4139"],"gpt_icon":0},{"id":"2517310944","title":"Needham:维持TScan Therapeutics(TCRX.US)评级,由买入调整至买入评级, 目标价由11.00美元调整至9.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517310944","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517310944?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:41","pubTimestamp":1741192881,"startTime":"0","endTime":"0","summary":"Needham:维持TScan Therapeutics(TCRX.US)评级,由买入调整至买入评级, 目标价由11.00美元调整至9.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06004148550592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","TCRX"],"gpt_icon":0},{"id":"1158846313","title":"TScan Therapeutics 2024年第四季度每股收益$(0.30)未达预期$(0.27),销售额$66.5万未达预期$135万","url":"https://stock-news.laohu8.com/highlight/detail?id=1158846313","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158846313?lang=zh_cn&edition=full","pubTime":"2025-03-05 20:15","pubTimestamp":1741176918,"startTime":"0","endTime":"0","summary":"TScan Therapeutics报告第四季度每股亏损$,未达到分析师一致预期的$,差异为11.11%。与去年同期每股亏损$相比,这是一个42.86%的下降。以上内容来自Benzinga Earnings专栏,原文如下:TScan $Therapeutics$ reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 11.11 percent. This is a 42.86 percent decrease over losses of $ per share from the same period last year. The company reported quarterly sales of $665.00 thousand which missed the analyst consensus estimate of $1.35 million by 50.74 percent. This is a 90.78 percent decre","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TCRX"],"gpt_icon":0},{"id":"2516658010","title":"Tscan Therapeutics, Inc.盘中异动 快速下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516658010","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516658010?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:41","pubTimestamp":1741016466,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时41分,Tscan Therapeutics, Inc.股票出现异动,股价快速下挫5.00%。Tscan Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.33%。其相关个股中,Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Entero Therapeutics Inc.涨幅较大,Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃,换手率分别为2303.18%、137.90%、130.65%,振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.,振幅分别为177.97%、70.53%、50.09%。Tscan Therapeutics, Inc.公司简介:TScan Therapeutics Inc 是一家生物制药公司,专注于开发用于治疗癌症患者的 T 细胞受体 工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303234107a25d5714&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303234107a25d5714&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","LENZ","BK4139","TCRX"],"gpt_icon":0},{"id":"2514382050","title":"Tscan Therapeutics, Inc.盘中异动 急速拉升5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514382050","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514382050?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:24","pubTimestamp":1740673455,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日00时24分,Tscan Therapeutics, Inc.股票出现异动,股价大幅拉升5.76%。Tscan Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.60%。其相关个股中,Alpha Tau Medical Ltd C/Wts 、Heron Therapeutics, Inc.、Pepgen Inc.涨幅较大,Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃,换手率分别为1654.91%、266.46%、112.45%,振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Quoin Pharmaceuticals Ltd、Pds Biotechnology Corporation,振幅分别为86.14%、47.79%、45.45%。Tscan Therapeutics, Inc.公司简介:TScan Therapeutics Inc 是一家生物制药公司,专注于开发用于治疗癌症患者的 T 细胞受体 工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502280024159632c887&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502280024159632c887&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","LENZ","BK4139","TCRX"],"gpt_icon":0},{"id":"2514586274","title":"Tscan Therapeutics, Inc.盘中异动 急速跳水5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514586274","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514586274?lang=zh_cn&edition=full","pubTime":"2025-02-27 04:27","pubTimestamp":1740601670,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日04时27分,Tscan Therapeutics, Inc.股票出现异动,股价快速跳水5.12%。Tscan Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.65%。其相关个股中,Enveric Biosciences, Inc.、Renovaro Inc.、Salarius Pharmaceuticals, Inc.涨幅较大,Enveric Biosciences, Inc.、Aeon Biopharma, Inc.、Organovo Holdings, Inc.较为活跃,换手率分别为6843.34%、332.19%、264.99%,振幅较大的相关个股有Enveric Biosciences, Inc.、Renovaro Inc.、Immatics N V C/Wts 01/07/2025 ,振幅分别为194.07%、81.11%、70.39%。Tscan Therapeutics, Inc.公司简介:TScan Therapeutics Inc 是一家生物制药公司,专注于开发用于治疗癌症患者的 T 细胞受体 工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227042751abde3a5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227042751abde3a5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4539","TCRX"],"gpt_icon":0},{"id":"2514077581","title":"Tscan Therapeutics, Inc.盘中异动 大幅下跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514077581","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514077581?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:54","pubTimestamp":1740412493,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时54分,Tscan Therapeutics, Inc.股票出现异动,股价急速下挫5.07%。Tscan Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.10%。其相关个股中,Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 涨幅较大,Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃,换手率分别为233.74%、100.01%、28.36%,振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ,振幅分别为151.09%、55.69%、53.34%。Tscan Therapeutics, Inc.公司简介:TScan Therapeutics Inc 是一家生物制药公司,专注于开发用于治疗癌症患者的 T 细胞受体 工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224235454962eac23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224235454962eac23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","TCRX","BK4539"],"gpt_icon":0},{"id":"2513101218","title":"Tscan Therapeutics, Inc.盘中异动 急速拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513101218","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513101218?lang=zh_cn&edition=full","pubTime":"2025-02-22 01:19","pubTimestamp":1740158358,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日01时19分,Tscan Therapeutics, Inc.股票出现异动,股价急速拉升5.02%。Tscan Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.45%。其相关个股中,Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Osr Holdings, Inc.、Invivyd, Inc.涨幅较大,Nkgen Biotech, Inc.、Aditxt, Inc.、Osr Holdings, Inc.较为活跃,换手率分别为239.47%、222.36%、128.50%,振幅较大的相关个股有Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Nkgen Biotech, Inc.,振幅分别为72.46%、57.50%、48.35%。Tscan Therapeutics, Inc.公司简介:TScan Therapeutics Inc 是一家生物制药公司,专注于开发用于治疗癌症患者的 T 细胞受体 工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222011919a24ed4eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222011919a24ed4eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TCRX","LENZ","BK4539"],"gpt_icon":0},{"id":"2512482724","title":"Tscan Therapeutics, Inc.盘中异动 临近午盘急速拉升5.44%报2.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512482724","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512482724?lang=zh_cn&edition=full","pubTime":"2025-02-20 00:32","pubTimestamp":1739982748,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日00时32分,Tscan Therapeutics, Inc.股票出现异动,股价急速拉升5.44%。Tscan Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.47%。其相关个股中,Osr Holdings, Inc.、Osr Holdings Inc C/Wts 02/09/2028 、Neurosense Therapeutics Ltd C/Wts 10/11/2026 涨幅较大,Aditxt, Inc.、Alzamend Neuro, Inc.、Osr Holdings, Inc.较为活跃,换手率分别为587.85%、244.73%、197.64%,振幅较大的相关个股有Osr Holdings Inc C/Wts 02/09/2028 、Osr Holdings, Inc.、Aditxt, Inc.,振幅分别为207.68%、159.49%、48.18%。Tscan Therapeutics, Inc.公司简介:TScan Therapeutics Inc 是一家生物制药公司,专注于开发用于治疗癌症患者的 T 细胞受体 工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220003228988b44bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220003228988b44bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TCRX","LENZ","BK4539","BK4139"],"gpt_icon":0},{"id":"2512160456","title":"Tscan Therapeutics, Inc.盘中异动 股价大涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512160456","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512160456?lang=zh_cn&edition=full","pubTime":"2025-02-19 00:38","pubTimestamp":1739896697,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日00时38分,Tscan Therapeutics, Inc.股票出现异动,股价大幅上涨5.12%。Tscan Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.58%。其相关个股中,Estrella Immunopharma Inc C/Wts 29/09/2028、Solid Biosciences Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大,Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃,换手率分别为395.73%、179.58%、150.74%,振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.,振幅分别为148.75%、92.00%、79.17%。Tscan Therapeutics, Inc.公司简介:TScan Therapeutics Inc 是一家生物制药公司,专注于开发用于治疗癌症患者的 T 细胞受体 工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219003817abd3ca90&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219003817abd3ca90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TCRX","BK4139","BK4539","LENZ"],"gpt_icon":0},{"id":"2511924536","title":"Tscan Therapeutics, Inc.盘中异动 早盘股价大涨5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511924536","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511924536?lang=zh_cn&edition=full","pubTime":"2025-02-14 23:56","pubTimestamp":1739548609,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日23时56分,Tscan Therapeutics, Inc.股票出现异动,股价大幅上涨5.39%。Tscan Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.73%。其相关个股中,Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Allogene Therapeutics, Inc.涨幅较大,Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.较为活跃,换手率分别为2607.67%、681.16%、512.63%,振幅较大的相关个股有Moleculin Biotech, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Klotho Neurosciences Inc C/Wts 21/06/2029 ,振幅分别为66.93%、54.40%、43.67%。Tscan Therapeutics, Inc.公司简介:TScan Therapeutics Inc 是一家生物制药公司,专注于开发用于治疗癌症患者的 T 细胞受体 工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214235649a2461420&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214235649a2461420&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TCRX","BK4539","LENZ","BK4139"],"gpt_icon":0},{"id":"2508178374","title":"Tscan Therapeutics, Inc.盘中异动 股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508178374","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508178374?lang=zh_cn&edition=full","pubTime":"2025-02-04 04:50","pubTimestamp":1738615816,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日04时50分,Tscan Therapeutics, Inc.股票出现波动,股价快速下挫5.06%。Tscan Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.31%。其相关个股中,Invivyd, Inc.、Hcw Biologics Inc.、Gh Research Plc涨幅较大,Cyclerion Therapeutics, Inc.、Hcw Biologics Inc.、Briacell Therapeutics Corp.较为活跃,换手率分别为1060.90%、763.13%、478.91%,振幅较大的相关个股有Invivyd, Inc.、Hcw Biologics Inc.、Briacell Therapeutics Corp.,振幅分别为188.15%、174.91%、63.94%。Tscan Therapeutics, Inc.公司简介:TScan Therapeutics Inc 是一家生物制药公司,专注于开发用于治疗癌症患者的 T 细胞受体 工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020404501696172fff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020404501696172fff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TCRX","BK4139","BK4539","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tscan.com","stockEarnings":[{"period":"1week","weight":-0.0648},{"period":"1month","weight":-0.1513},{"period":"3month","weight":-0.4261},{"period":"6month","weight":-0.3484},{"period":"1year","weight":-0.6656},{"period":"ytd","weight":-0.6678}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"TScan Therapeutics, Inc.于2018年4月17日在特拉华州注册成立。该公司是一家临床前阶段的生物制药公司,专注于开发强大的T细胞受体工程T细胞或TCR-T疗法,用于治疗癌症患者。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.007644},{"month":2,"riseRate":0.5,"avgChangeRate":0.157126},{"month":3,"riseRate":0.25,"avgChangeRate":-0.197008},{"month":4,"riseRate":0.5,"avgChangeRate":-0.003964},{"month":5,"riseRate":0.75,"avgChangeRate":0.125017},{"month":6,"riseRate":0.5,"avgChangeRate":-0.058009},{"month":7,"riseRate":0.75,"avgChangeRate":0.178095},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114317},{"month":9,"riseRate":0.6,"avgChangeRate":0.003702},{"month":10,"riseRate":0.6,"avgChangeRate":0.083419},{"month":11,"riseRate":0.4,"avgChangeRate":-0.001328},{"month":12,"riseRate":0,"avgChangeRate":-0.250982}],"exchange":"NASDAQ","name":"Tscan Therapeutics, Inc.","nameEN":"Tscan Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tscan Therapeutics, Inc.(TCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Tscan Therapeutics, Inc.(TCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Tscan Therapeutics, Inc.,TCRX,Tscan Therapeutics, Inc.股票,Tscan Therapeutics, Inc.股票老虎,Tscan Therapeutics, Inc.股票老虎国际,Tscan Therapeutics, Inc.行情,Tscan Therapeutics, Inc.股票行情,Tscan Therapeutics, Inc.股价,Tscan Therapeutics, Inc.股市,Tscan Therapeutics, Inc.股票价格,Tscan Therapeutics, Inc.股票交易,Tscan Therapeutics, Inc.股票购买,Tscan Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tscan Therapeutics, Inc.(TCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Tscan Therapeutics, Inc.(TCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}